Author:
Lindenmayer Jean-Pierre,Burke Eugene,Tsuboyama Gabriel,Chahal Yasmeen,Grewal Harpreet Kaur
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Pharmacology (medical),Psychiatry and Mental health
Reference9 articles.
1. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study;Mov Disord,2015
2. Efficacy of valbenazine (NBI-98854) in treating subjects with tardive dyskinesia and schizophrenia or schizoaffective disorder;Psychopharmacol Bull,2017
3. A long-term, open-label study of valbenazine for tardive dyskinesia;CNS Spectr,2021
4. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: relevance to tardive dyskinesia and antipsychotic action;Pharmacol Biochem Behav,2020
5. Regulation of the dopamine and vesicular monoamine transporters: pharmacological targets and implications for disease;Pharmacol Rev,2015
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献